ArticleEuropean journal of hospital pharmacy : science and practice2023

Predictive value of immune-related adverse events during pembrolizumab treatment in non-small cell lung cancer.

Carmen Maria Valencia Soto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.